Status:
RECRUITING
CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma
Lead Sponsor:
Children's Cancer Group, China
Collaborating Sponsors:
Shanghai Children's Medical Center
Conditions:
Hodgkin Lymphoma
Eligibility:
All Genders
1-18 years
Phase:
PHASE4
Brief Summary
The incidence of Hodgkin's lymphoma (HL) in Chinese children and adolescents is only 1 / 10 of that in Europe and the United States, which is a "rare" childhood tumor. Due to the "drug shortage" and e...
Detailed Description
In this study, enrolled patients from age 1 through 18 years with newly diagnosed and biopsy-proven HL are stratified into 3 risk groups according to 3 COG published trials: AHOD0831 (high risk-all An...
Eligibility Criteria
Inclusion
- Patient must be ages 1 to 18 years at the time of diagnosis; Newly diagnosed, histologically confirmed Hodgkin disease (No nodular lymphocyte-predominant Hodgkin lymphoma)
Exclusion
- Patients have received prior cytotoxic chemotherapy for the current diagnosis or any cancer, if any steroid applied, total prior steroids dosage \< Prednisone 80 mg/m2; Patients have congenital immunodeficiency, HIV infection, or prior organ transplant; Patients have overwhelming infection, and a life expectancy of \< 2 weeks
Key Trial Info
Start Date :
April 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04726501
Start Date
April 1 2018
End Date
December 31 2027
Last Update
February 13 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Second University Hospital, Sichuan University, Chengdu, China
Chengdu, China
2
Nanjing Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Nanjing, China
3
Shanghai Children's Medical Center
Shanghai, China, 200127